AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 211 min read$IART

Integra: Q3 Earnings Snapshot

Integra LifeSciences (IART) reported Q3 net income of $14.9M, or 19 cents per share, beating analyst estimates of 56 cents per share. Revenue was $411.2M, missing expectations of $414.5M. The company forecasts full-year earnings of $2.30-$2.40 per share and revenue of $1.63B-$1.65B.

Original reporting
finance.yahoo.com
Published Oct 21, 2026, 10:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 10:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Integra: Q3 Earnings Snapshot — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$IARTNeutralMed
01

Why it matters

The earnings beat on a per‑share basis may attract short‑term buying, while the revenue shortfall could prompt caution.

02

Market read

First‑report earnings data for a mid‑cap med‑device company; relevant for traders monitoring earnings season.

03

What to watch

Guidance range remains broad; investors may focus on upcoming product pipeline and cost controls.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Integra LifeSciences is a medical device maker listed on NASDAQ (IART). The article provides its Q3 earnings release.

Company-level read

Ticker impact

$IARTNeutralHigh confidence
Context

Integra LifeSciences reported Q3 earnings with EPS beat (59¢ vs 56¢ est) but revenue miss ($411.2M vs $414.5M est) and gave FY guidance of $2.30‑$2.40 EPS.

Expected impact

likely modest upside as market prices in the earnings beat, tempered by revenue miss

Evidence & confidence

First‑report earnings numbers provide new data; beat on earnings is a positive catalyst, but revenue miss introduces downside risk.

Market effects

Sector

Medical device sector may see mixed reaction as earnings beat offsets revenue weakness.

Regional

U.S. market participants will adjust expectations for Integra and comparable med‑device peers.

Global

Limited to investors tracking U.S. med‑device stocks.

Counterpoint

What could challenge this read

Revenue miss could signal slowing demand, suggesting a pullback despite EPS beat.

Key entities

  • company
    Integra LifeSciences Holdings Corp.

    Medical device manufacturer reporting Q3 results.

Read at source← All news

StoryIntegra LifeSciences reports Q3 2026 results, cites $7 M flood hit, completes $2.1 B refinancing and trims Q4 outlook

Also covered by

5 outlets

Related articles

OCT 21
$IARTMed

Integra LifeSciences (IART) Reports Q3 Revenue In Line with Guid

Integra LifeSciences (IART) reported Q3 revenue of $411M, meeting the lower end of its guidance. The company lowered its full-year revenue outlook by $30M due to operational disruptions. IART's P/S ratio is 0.57, below historical and industry averages. The company has a GF Score of 69, indicating mixed fundamentals with strengths in momentum and profitability but weaknesses in growth and financial strength. Insider activity shows net buying of $0.1M, while institutional interest is mixed.

gurufocus.com3 min
OCT 21
$IARTHighAI 8/10

Integra (IART) Q3 2026 Earnings Call Transcript

Integra (IART) reported Q3 2026 adjusted EPS of $0.59, with revenue at $411.2M, impacted by Cincinnati flooding. Operating cash flow was $96M. Full-year revenue guidance was reduced by $30M due to flooding and mixed portfolio performance. Tissue Reconstruction revenue is expected to be flat. The company reduced leverage to 3.8x and completed debt refinancing, strengthening its balance sheet.

finance.yahoo.com3 min
OCT 21
$IARTHigh

Integra Life falls as tissue reconstruction woes add to flooding worries in Q3

Integra LifeSciences (IART) shares fell to a May low after Q3 2026 results missed revenue estimates. Revenue was $411.2M, up 2% YoY but below consensus by $0.9M, impacted by a $7M headwind and weaker Tissue Reconstruction performance. Gross margin declined 500 bps to 51%, while adjusted net income rose 12% YoY to $46.4M, beating estimates by $0.03 per share. Q4 and full-year outlooks were set below consensus.

tradingview.com2 min
OCT 21
Med

Integra LifeSciences Holdings Corporation Q3 2026 Earnings Call Summary

Integra LifeSciences reported Q3 2026 earnings, citing a $7M revenue hit from Cincinnati flooding. Neurosurgery grew 6.5% organically, offsetting weaker segments. Tissue Reconstruction showed mixed results. The company refinanced $2.1B in debt. Management expects 2027 revenue to be impacted by $15M-$20M in Q1 and Q2 due to ongoing disruption. Earnings growth is projected to be supported by cost savings and a SurgiMend relaunch.

finance.yahoo.com2 min
OCT 21
$IARTMed

Why Integra LifeSciences (IART) stock is falling today

Integra LifeSciences (IART) shares fell 7.3% after reporting Q3 revenue of $411.2M, meeting expectations, and adjusted EPS of $0.59, beating estimates. The company cited plant flooding and operational disruptions, projecting Q4 revenue of $413M-$433M, below analyst estimates of $433.2M. Rising borrowing costs also weighed on investor sentiment.

financialcontent.com2 min